Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) and CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.
Valuation & Earnings
This table compares Ernexa Therapeutics and CRISPR Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ernexa Therapeutics | N/A | N/A | -$14.08 million | ($14.35) | -0.14 |
| CRISPR Therapeutics | $3.51 million | 1,377.07 | -$581.60 million | ($4.76) | -10.50 |
Ernexa Therapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current recommendations for Ernexa Therapeutics and CRISPR Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ernexa Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| CRISPR Therapeutics | 1 | 7 | 9 | 2 | 2.63 |
Ernexa Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 1,426.72%. CRISPR Therapeutics has a consensus target price of $65.75, suggesting a potential upside of 31.53%. Given Ernexa Therapeutics’ higher possible upside, equities research analysts clearly believe Ernexa Therapeutics is more favorable than CRISPR Therapeutics.
Insider & Institutional Ownership
70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 0.5% of Ernexa Therapeutics shares are owned by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Ernexa Therapeutics and CRISPR Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ernexa Therapeutics | N/A | -305.93% | -169.86% |
| CRISPR Therapeutics | -3,368.72% | -24.39% | -18.25% |
Risk and Volatility
Ernexa Therapeutics has a beta of 2.75, indicating that its share price is 175% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500.
Summary
CRISPR Therapeutics beats Ernexa Therapeutics on 8 of the 14 factors compared between the two stocks.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
